RAYNHAM, Mass., Nov. 14, 2011 /PRNewswire/ -- Codman & Shurtleff, Inc. (Codman), a global neuroscience and neurovascular company, today announced the launch of the CODMAN® CERTAS™ Programmable Valve, a shunt used in the treatment of congenital or acquired hydrocephalus, an excess accumulation of cerebrospinal fluid (CSF) in the brain.
Over the last 15 years, Codman shunts have been used to treat approximately 150,000 patients suffering from hydrocephalus in the U.S. The CODMAN® CERTAS Programmable Valve is the latest offering in the company's portfolio of products for the treatment of hydrocephalus, and provides surgeons with another choice when determining the appropriate course of treatment for patients.
The CODMAN® CERTAS Programmable Valve has eight settings to control the rate of drainage of CSF from the brain to the abdomen. The eighth setting is a very high setting comparable to the valve being "off." The new device, which is resistant to unintended changes to settings during magnetic resonance imaging (MRI)(1), will be offered alongside the CODMAN® HAKIM® Programmable Valve*, a shunt that offers 18 settings.
"The CODMAN® CERTAS Valve is easy to program and still provides doctors with enough settings to make very fine adjustments in pressure to get the best resolution of symptoms after shunt implantation," said George Jallo, MD, Clinical Director of Pediatric Neurosurgery at Johns Hopkins Hospital, Baltimore. "A device that is resistant to MRI is a big plus for patients."
The CODMAN® CERTAS Programmable Valve can be integrated with CODMAN® SIPHONGUARD® to prevent excessive flow of CSF while draining, and Codman's BACTISEAL® Catheters.
"Hydrocephalus is a complex and debilitating condition. We are committed to expanding our solutions to help surgeons advance the treatment of patients who have varying needs," said P. Laxmin La
|SOURCE Codman & Shurtleff, Inc.|
Copyright©2010 PR Newswire.
All rights reserved